drugset / Trial / NCT04885647
A Study of YPEG-rhEPO in Patients Suffered From Anemia Due to Chronic Kidney Disease
Phase 2
Completed
60 enrolled
Xiamen Amoytop Biotech Co., Ltd.
First Affiliated Hospital of Zhejiang University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the effectiveness and safety of YPEG rhEPO, a recombinant human erythropoietin pegylated by Y shape polyethylene glycol, in patients with anemia due to Chronic Kidney Disease (CKD), assessed by hemoglobin maintenance, adverse events and health-related quality of life.
Timeline
- Start
- 2021-03-12
- Primary completion
- 2022-01-05
- Completion
- 2022-01-05
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | YPEG rhEPO | Protein / enzyme biologic | — | Subcutaneous |